Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.

Pharmacological research - 1 Mar 2023

Han Yefan, Hu Anni, Qu Yi, Xu Qianqian, Wang Hang, Feng Yin, Hu Yili, He Li, Wu Hao, Wang Xinzhi

Abstract excerpt

Patients with NPM1 gene mutation-associated acute myeloid leukemia (AML), particularly those over the age of 60, have no viable targeted therapeutic choices. In this study, we identified HEN-463, a sesquiterpene lactone derivative specific targets AML with this gene mutation. This compound inhibits the interaction of LAS1-NOL9 by covalently binding to the C264 site of the ribosomal biogenesis-related protein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Ribosomal Proteins

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 36796466
DOI: 10.1016/j.phrs.2023.106700

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.PMID 36796466Read ↗

Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation.Semantic proximity Read ↗

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AMLSemantic proximity Read ↗

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growthSemantic proximity Read ↗

A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.Semantic proximity Read ↗

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in <i>NPM1</i> -mutated AMLSemantic proximity Read ↗

NPM1 mutation promotes creatine anabolism by FTO-dependent m6A demethylation to drive macrophage M2 polarization in acute myeloid leukemia.Semantic proximity Read ↗

Functions of the native NPM1 protein and its leukemic mutant.Semantic proximity Read ↗

N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.Semantic proximity Read ↗

Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.Semantic proximity Read ↗

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia.Semantic proximity Read ↗

Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibitionSemantic proximity Read ↗

EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.